The Journal of Immunology · 2005 · 467 citations · 44 references
Life SciencesImmunologyOncologyCancer ImmunologyMetastasisTumor ImmunologyCytokines In Tumor ImmunityMacrophage BiologyMyeloid-derived Suppressor CellsT Cell Responses To TumorsTumor ImmunopathologyTumor-associated MacrophagesCancer-associated MacrophagesCell ActivationMyeloid-derived Suppressor Cell ActivationMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell ImmunosuppressionMyeloid-derived Suppressor Cell PhenotypeMyeloid-derived Suppressor Cell-mediated SuppressionSurgical Removal Of Tumors
More than 60% of STAT6(-/-) mice immunologically reject spontaneous metastatic mammary carcinoma and survive indefinitely if their primary tumors are removed, whereas 95% of STAT6-competent BALB/c mice succumb to metastatic disease. BALB/c and STAT6-deficient mice with primary tumors have elevated levels of Gr1(+)CD11b(+) myeloid suppressor cells (MSCs), which inhibit T cell activation. After removal of primary tumor, MSC levels revert to baseline in STAT6-deficient mice, but remain elevated in BALB/c mice. The decrease is IFN-gamma dependent, as is the reduction in metastatic disease. Neither BALB/c nor STAT6-deficient MSCs produce inducible NO synthase; however, both produce arginase and reactive oxygen species. STAT6-deficient mice produce M1 macrophages, which contain high levels of NO and are tumoricidal, whereas BALB/c mice produce M2 macrophages, which make arginase and are not tumoricidal. Immunity in STAT6-deficient mice requires the activation of NO-producing M1 macrophages that are tumoricidal, the reduction in MSC levels to baseline after surgical removal of primary tumor, and the activation of tumor-specific T cells. These mechanisms occur in STAT6(-/-) mice because STAT6 deficiency prevents signaling through the type 2 IL-4Ralpha, thereby blocking the production of arginase and promoting the synthesis of NO.
44
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Charles D. Mills, Kristi Kincaid, Jennifer Alt et al. · The Journal of Immunology · 2000 · 3.2K citations
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Thomas Decker, Marie‐Luise Lohmann‐Matthes · Journal of Immunological Methods · 1988 · 1.4K citations